Novartis AG (NVS)
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General